On June 27, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending May 31, 2024. The company announced a decrease in adjusted earnings per share (EPS) by 36.6% on a constant currency basis compared to the previous year, citing lower sale-leaseback gains, a challenging U.S. retail environment, and recent pharmacy industry trends as contributing factors. Despite these challenges, third-quarter sales saw a year-over-year increase of 2.6% to $36.4 billion. WBA also lowered its fiscal 2024 adjusted EPS guidance to $2.80 to $2.95, reflecting the ongoing industry challenges and a worse-than-expected U.S. consumer environment. Additionally, the company is finalizing a significant multiyear footprint optimization program to close certain underperforming U.S. stores and is launching a U.S. Retail Pharmacy action plan to invest in and improve customer and patient experience. The company's CEO, Tim Wentworth, expressed confidence in the team and strategy to lead a business turnaround. The financial report was accompanied by a conference call and webcast discussing the results and related matters.

On June 27, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending May 31, 2024. The company announced a decrease in adjusted earnings per share (EPS) by 36.6% on a constant currency basis compared to the previous year, citing lower sale-leaseback gains, a challenging U.S. retail environment, and recent pharmacy industry trends as contributing factors. Despite these challenges, third-quarter sales saw a year-over-year increase of 2.6% to $36.4 billion. WBA also lowered its fiscal 2024 adjusted EPS guidance to $2.80 to $2.95, reflecting the ongoing industry challenges and a worse-than-expected U.S. consumer environment. Additionally, the company is finalizing a significant multiyear footprint optimization program to close certain underperforming U.S. stores and is launching a U.S. Retail Pharmacy action plan to invest in and improve customer and patient experience. The company's CEO, Tim Wentworth, expressed confidence in the team and strategy to lead a business turnaround. The financial report was accompanied by a conference call and webcast discussing the results and related matters.